Fifth Third Bancorp Decreases Stock Holdings in Genmab A/S (NASDAQ:GMAB)

Fifth Third Bancorp reduced its position in Genmab A/S (NASDAQ:GMAB) by 18.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 36,136 shares of the company’s stock after selling 8,440 shares during the period. Fifth Third Bancorp’s holdings in Genmab A/S were worth $754,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. SG Americas Securities LLC lifted its position in shares of Genmab A/S by 82.7% in the fourth quarter. SG Americas Securities LLC now owns 26,396 shares of the company’s stock valued at $551,000 after acquiring an additional 11,949 shares in the last quarter. Crossmark Global Holdings Inc. lifted its holdings in shares of Genmab A/S by 8.8% in the fourth quarter. Crossmark Global Holdings Inc. now owns 41,622 shares of the company’s stock worth $868,000 after buying an additional 3,377 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after acquiring an additional 1,051 shares during the last quarter. MML Investors Services LLC grew its stake in Genmab A/S by 5.4% during the third quarter. MML Investors Services LLC now owns 73,261 shares of the company’s stock valued at $1,786,000 after acquiring an additional 3,785 shares in the last quarter. Finally, XTX Topco Ltd increased its holdings in Genmab A/S by 116.4% in the 3rd quarter. XTX Topco Ltd now owns 25,429 shares of the company’s stock valued at $620,000 after acquiring an additional 13,678 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Up 1.4 %

Shares of GMAB opened at $19.85 on Thursday. The business has a fifty day moving average of $21.07 and a 200 day moving average of $23.82. The company has a market cap of $13.14 billion, a PE ratio of 19.27, a P/E/G ratio of 0.57 and a beta of 0.97. Genmab A/S has a 52-week low of $19.02 and a 52-week high of $31.88.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The firm had revenue of $816.10 million during the quarter, compared to the consensus estimate of $838.20 million. During the same quarter last year, the business posted $0.47 EPS. As a group, research analysts anticipate that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

GMAB has been the subject of a number of research analyst reports. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Redburn Atlantic started coverage on Genmab A/S in a report on Tuesday, October 8th. They set a “buy” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Thursday, January 23rd. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $48.00 target price (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.